Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30492983 | 1.00 | KMT2A (0.55) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL18239875 | 0.85 | HPGD (0.49) | KMT2AMEN1GAAALDH1A1SMN1; SMN2 | |
| SCHEMBL7956482 | 0.82 | MEN1 (0.65) | KMT2AMEN1GAAALDH1A1ATM | |
| SCHEMBL31401825 | 0.80 | MEN1 (0.50) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL27703451 | 0.78 | CA1 (0.51) | KMT2AMEN1CA1CA2CA9 | |
| SCHEMBL20373539 | 0.78 | MEN1 (0.51) | KMT2AMEN1GAACA1CA2 | |
| SCHEMBL21676273 | 0.78 | KDM4E (0.53) | KMT2AMEN1GAAALDH1A1ATM | |
| SCHEMBL20647549 | 0.78 | HTT (0.56) | KMT2AMEN1GAAALDH1A1KDM4E | |
| SCHEMBL23261794 | 0.77 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL8541790 | 0.76 | KDM4E (0.65) | KMT2AMEN1CA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601224-B1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2023-07-05 | — | — | EP | disclosed |
| US-11000511-B2 | Chemical compounds as antibiotics | ANTABIO SAS (FR) | 2021-05-11 | — | — | US | disclosed |
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2020-05-21 | — | — | US | disclosed |
| CN-110914238-A | Compounds as antibiotics | 安塔比奥公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3601224-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | Antabio SAS (FR) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018172423-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | ANTABIO SAS (FR) | 2018-09-27 | — | — | WO | disclosed |
| US-8242116-B2 | Fused thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-08-14 | — | — | US | disclosed |
| US-8168634-B2 | Thiazole derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2035436-B1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | US | disclosed |
| US-20100240664-A1 | SOLUBILIZED TOPOISOMERASE POISON AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240664-A1 | SOLUBILIZED TOPOISOMERASE POISON AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | US | disclosed |
| EP-2084155-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008047109-A1 | THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155509-A1 | CHEMICAL COMPOUNDS AS ANTIBIOTICS | MRPL21, CFTR, H1-0 | KMT2A 825/4885MEN1 569/4885GAA 3219/4885 |
| US-20100240664-A1 | SOLUBILIZED TOPOISOMERASE POISON AGENTS | TOP1, TOP2A, TOP2B | KMT2A 1532/4885MEN1 1994/4885GAA 426/4885 |
| US-20100137302-A1 | Fused Thiazole Derivatives as Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | KMT2A 2966/4885MEN1 1461/4885GAA 1760/4885 |
| US-11000511-B2 | Chemical compounds as antibiotics | MRPL21, CFTR, H1-0 | KMT2A 825/4885MEN1 569/4885GAA 3219/4885 |
| US-20100298310-A1 | Thiazole Derivatives as Kinase Inhibitors | TEC, BTK, PI4KA | KMT2A 1926/4885MEN1 1425/4885GAA 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.